NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer
- 5.1k Downloads
The purpose of this document is to present a current and comprehensive set of practice recommendations for effective genetic cancer risk assessment, counseling and testing for hereditary breast and ovarian cancer. The intended audience is genetic counselors and other health professionals who care for individuals with, or at increased risk of, hereditary breast and/or ovarian cancer.
KeywordsHereditary breast and ovarian cancer BRCA1 BRCA2 Cancer genetic counseling Risk assessment Medical management
The practice guidelines of the National Society of Genetic Counselors (NSGC) are developed by members of the NSGC to assist genetic counselors and other health care providers in making decisions about appropriate management of genetic concerns, including access to and/or delivery of services. Each practice guideline focuses on a clinical or practice-based issue, and is the result of a review and analysis of current professional literature believed to be reliable. As such, information and recommendations within the NSGC practice guidelines reflect the current scientific and clinical knowledge at the time of publication, are only current as of their publication date, and are subject to change without notice as advances emerge.
In addition, variations in practice, which take into account the needs of the individual patient and the resources and limitations unique to the institution or type of practice, may warrant approaches, treatments and/or procedures that differ from the recommendations outlined in this guideline. Therefore, these recommendations should not be construed as dictating an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. Genetic counseling practice guidelines are never intended to displace a health care provider’s best medical judgment based on the clinical circumstances of a particular patient or patient population. Practice guidelines are published by NSGC for educational and informational purposes only, and NSGC does not “approve” or “endorse” any specific methods, practices, or sources of information.
© 2012 National Society of Genetic Counselors. All rights reserved. This document may not, in whole or in part, be reproduced, copied or disseminated, entered into or stored in a computer database or retrieval system, or otherwise utilized without the prior written consent of the NSGC.
- ACOG Committee on Practice Bulletins. Hereditary breast and ovarian cancer syndrome (2009) Gynecologic Oncology, 113(1), 6–11.Google Scholar
- ACOG Practice Bulletin No. 103: Hereditary Breast and Ovarian Cancer Syndrome (2009). Obstetrics and Gynecology, 113(4), 957–966.Google Scholar
- American College of Medical Genetics and Genomics. (2012). Policy statement: points to consider in the clinical application of genomic sequencing. Genetics in Medicine, 14(8), 759–761.Google Scholar
- American Society of Clinical Oncology. (2003). American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21, 2397–2406.Google Scholar
- American Society of Clinical Oncology. (2010). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28, 893–901.Google Scholar
- Americans with Disabilities Act of 1990; https://doi.org/www.ada.gov/pubs/ada.htm.
- Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in cases series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72(5), 1117–1130.PubMedPubMedCentralGoogle Scholar
- Atchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Arun, B. K. (2008). Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. Journal of Clinical Oncology, 26, 4282–4288.PubMedGoogle Scholar
- Begg, C. B., Haile, R. W., Borg, A., Malone, K. E., Concannon, P., et al. (2009). Variation of breast cancer risk among BRCA1/2 carriers. An investigation by the WECARE Study Group. JAMA, 299(2), 194–201.Google Scholar
- Berliner, J. L., & Fay, A. M. (2007). Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 16(3), 241–260.Google Scholar
- Fasouliotis, S. J., & Schenker, J. G. (2000). BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management. Obstetrical & Gynecological Survey, 55(6), 373–384.Google Scholar
- Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., et al. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examine annually. Journal of the National Cancer Institute, 81, 1879–1886.PubMedPubMedCentralGoogle Scholar
- GeneTests (2012). https://doi.org/www.genetests.org.
- Health Insurance Portability and Accountability Act of 1996, Pub L No 104–191; US Department of Health and Human Services: OCR Privacy Brief. Summary of the HIPAA Privacy Rule. https://doi.org/www.hhs.gov/ocr/privacysummary.pdf.
- H.R. 493 (110th): Genetic Information Nondiscrimination Act of 2008, accessed at https://doi.org/www.govtrack.us/congress/bills/110/hr493.
- Lindor & Greene (2008). SPECIAL ARTICLE. The Concise Handbook of Family Cancer Syndromes. Journal of the National Cancer Institute Monographs, No. 38.Google Scholar
- Lowery, M., Kelsen, D., Stadler, Z., Yu, K. H., Janjigian, Y. Y., Ludwig, E., et al. (2011). An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. The Oncologist, 16, 1397–1402.PubMedPubMedCentralGoogle Scholar
- National Cancer Institute (2009). Breast Cancer Prevention. Description of Evidence. https://doi.org/www.cancer.gov/cancertopics/pdq/genetics/breast-and ovarian/HealthProfessional#Section_6
- National Comprehensive Cancer Network (NCCN) Guidelines, Inc. (2012). Hereditary Breast and/or Ovarian Cancer Syndrome (v.3.2012). https://doi.org/www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
- National Society of Genetic Counselors (NSGC) Code of Ethics (adopted 1/92; revised 1/06) https://doi.org/www.nsgc.org/Advocacy/NSGCCodeofEthics/tabid/155/Default.aspx
- Patenaude, A. F. (2005). Genetic testing for cancer: Psychological approaches for helping patients and families. Washington, DC: American Psychological Association.Google Scholar
- Riley, B. D., Culver, J. O., Skrzynia, C., Senter, L. A., Peters, J. A., Costalas, J. W., et al. (2012). Essential elements of genetic cancer risk assessment, counseling and testing: updated recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 21(2), 151–161.PubMedGoogle Scholar
- Saslow, D., Boetes, C., Burke, W., et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians, 57(57), 75–89.Google Scholar
- U.S. Preventive Services Task Force. (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Annals of Internal Medicine, 143(5), 355–361.Google Scholar
- van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F., et al. (2005). Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON). Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. Journal of Medical Genetics, 42(9), 711–719.PubMedPubMedCentralGoogle Scholar